Boston Therapeutics, Inc. (OTCQB: BTHE) is a pharmaceutical company focused on the development, manufacturing and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs in diabetes. SNNLive spoke with David Platt, Ph.D., Chairman and CEO of Boston Therapeutics, Inc. at the SeeThruEquity Winter MicroCap Investor Conference 2015 in New York City, NY.
Dr. Platt begins with an overview of the company, “Boston Therapeutics developed two technologies in diabetes. One is for preventing from getting the sugar increase in the blood stream like any diabetes drugs, and the second technology is anti-necrosis drug which is oxygen therapeutics.”
He continues with what’s new with Boston Therapeutics, “We went to the FDA with our data in Phase II, which we’ll publish in the peer-review journal, and the FDA approved what you call 'adaptive clinical trial.' It means that we have 360 patients to get an NDA or get it approved. We will do, in the adaptive clinical trial, we’ll do one hundred patients. The primary site is Joslin Medical Diabetes Center in Boston."
He describes how the size of the market, “We’re talking about the size of about 80 to 100 million people, actually it’s 100 million people in the US, and about half a billion around the world. We’re talking about pre-diabetics or those patients that are close to being diabetic, it’s a blood sugar - have a blood sugar problem that it’s going up significantly. Eventually, they turn out to be diabetic. It’s an epidemic worldwide of consuming too much sugar...There is no drug today to address a pre-diabetic exist or approved. For that, we need to show the reduction of A1C, which is the standard of care of measuring and get it approved by the FDA.”
Dr. Platt explains how the drug works and how it differs from others, “We block the enzyme in the intestine that digests sugar in food and as a consequence less sugar goes into the bloodstream. This is not like other diabetic drug which all systemic, it mean they go into the bloodstream and affect mechanism of pancreas, insulin, liver, brain and kidney. We are completely non-systemic, only in the intestine.” For more information, check out their website: www.Bostonti.com
Since speaking with Dr. Platt, the company has made the following announcements:
© 2017 Stock News Now
Supported by Superior Web Solutions